Skip to main content

Table 3 Efficacy Outcomes

From: World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis

Complete Clinical Cure
Study Patients Comparison Follow up RR 95% CI p value
Balagon, 2010 [18] PB MDT vs. 28 days of RFP + ofloxocin for 4w then 5 months of placebo 6 m 4.2 2.25–7.85 < 0.05
12 m 0.93 0.80–1.09 0.38
Bathe, 1986 [19] MDT vs. MDT+ clofazimine in alternative days for 6 m 6 m 1.25 0.77–2.04 0.37
24 m 1.09 0.93–1.27 0.29
Orege, 1990 [26] MDT vs. Modified MDT (MDT + RFP + dapsone)a 6 m 0.76 0.61–0.95 0.02
Clinical Improvement
Study Patients Comparison Follow up MDT Control
Rao, 2009 [27] PB MDT vs RFP + dapsone + clofazimine (good) 24 m 6/11 (52%) 7/9 (78%)
MDT vs RFP + dapsone + clofazimine (moderate) 3/11 (27%) 2/9 (22%)
MB MDT vs RFP + dapsone + clofazimine (good) 13/17 (77%) 1/4 (25%)
MDT vs RFP + dapsone + clofazimine (moderate) 3/17 (17%) None
Sampoonachut, 1997 [36] MDT vs. MDT + ofloxacin. 36 m 66.70% 73.30%
MDT vs. ofloxacin + clofazimine, then MDT 66.70% 76.50%
Tejasvi, 2006 [39] MDT vs. RFP + Sparfloxacin + clarithromycin + minocycline 12 m 66.66% 73.92%
Villahermosa, 2004 [40]b MDT vs. ROM 96 m 22 points 20 points
Relapse
Study Patients Comparison Follow up RR 95% CI p value
Balagon, 2010 [18] PB MDT vs. 28 days of RFP + ofloxacin for 4w then 5 m of placebo 12 m 1.76 0.16–18.88 0.64
Katoch, 1999 [22] MDT vs. MDT+ clofazimine 24 m 5 0.24–103.28 0.3
Kumar, 2015 [23] MDT vs. ROM 24 m 0.5 0.05–5.45 0.57
96 m 1.7 0.94–3.07 0.08
Manickam, 2012 [24] MDT vs. ROM 6 m 1.43 0.56–3.64 0.46
Fajardo 2009 [30] MB MDT 2y vs. MDT 1y + 1 month daily RFP/ofloxacin 144 m 0.51 0.05–5.46 0.58
MDT 2y vs. 1 month daily RFP/ofloxacin 0.11 0.02–0.87 0.04
MDT 2y vs. MDT 1 y 0.05 0.01–0.37 < 0.05
Olivera Penna, 2017 [35] MDT vs. RFP+ dapsone + clofazimine × 6 m 60 m 0.16 0.02–1.29 0.08
Souza Cunha, 2012 [38] MDT 1y vs. MDT x 2y 84 m 2.59 0.13–52.17 0.53
MDT 1y vs. MDT + ofloxacin 1.04 0.15–7.10 0.97
MDT 1y vs. ofloxacin + RFP 0.13 0.03–0.51 < 0.05
Villahermosa, 2004 [40] MDT vs. ROM 96 m No events reported
BI
Study Patients Comparison Follow up MD 95% CI p value
Bathki, 1992 [29] MB MDT vs. MDT + vaccine 24 m 1.3 0.48, 2.12 < 0.05
Gunawan 2018 [32] MDT vs. CDC 3 m 0.03 −0.03,0.09 0.75
Jadav, 1992 [33] MDT vs. RFP + dapsone + clofazimine 24 m 0.41 0.12, 0.70 < 0.05
Olivera Penna, 2017 [35] MDT vs. RFP+ dapsone + clofazimine × 6 m 60 m − 0.15 −1.06,0.76 0.34
Sampoonachut, 1997c [36] MDT vs. MDT + ofloxacin. 36 m −0.07 − 0.48, 0.34 0.74
MDT vs. Ofloxacin + clofazimine, then MDT −0.68 −1.10, − 0.26 < 0.05
Shaw, 2003c [37] MDT vs. RFP + clofazimine+ acedapsone + dapsone 24 m 0.1 − 0.34, 0.54 0.66
  1. Abbreviations. - BI Bacillary index, CDC Clarithromycin+ dapsone+ clofazimine, m Months, MDT Multidrug treatment, ROM Rifampin, ofloxacin and minocycline
  2. aIncluded a period of direct observation
  3. bMaximum Improvement score at the end of treatment; no other information reported
  4. cSD not reported